Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer

Purpose: - - For rare cancers such as neuroendocrine bladder cancer treatment options are limited due partly to the lack of preclinical models. Techniques to amplify rare primary neuroendocrine bladder cancer cells could provide novel tools for the discovery of drug and diagnostic targets. We devel...

Full description

Saved in:
Bibliographic Details
Main Authors: Höfner, Thomas (Author) , Macher-Göppinger, Stephan (Author) , Klein, Corinna (Author) , Rigo Watermeier, Teresa (Author) , Eisen, Christian (Author) , Pahernik, Sascha (Author) , Hohenfellner, Markus (Author) , Trumpp, Andreas (Author) , Sprick, Martin (Author)
Format: Article (Journal)
Language:English
Published: 1 Dec 2013
In: The journal of urology
Year: 2013, Volume: 190, Issue: 6, Pages: 2263-2270
ISSN:1527-3792
DOI:10.1016/j.juro.2013.06.053
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.juro.2013.06.053
Verlag, lizenzpflichtig, Volltext: https://www.auajournals.org/doi/10.1016/j.juro.2013.06.053
Get full text
Author Notes:Thomas Hofner, Stephan Macher-Goeppinger, Corinna Klein, Teresa Rigo-Watermeier, Christian Eisen, Sascha Pahernik, Markus Hohenfellner, Andreas Trumpp, and Martin R. Sprick

MARC

LEADER 00000caa a2200000 c 4500
001 1762793458
003 DE-627
005 20240414193232.0
007 cr uuu---uuuuu
008 210713s2013 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.juro.2013.06.053  |2 doi 
035 |a (DE-627)1762793458 
035 |a (DE-599)KXP1762793458 
035 |a (OCoLC)1341418984 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Höfner, Thomas  |d 1979-  |e VerfasserIn  |0 (DE-588)132286963  |0 (DE-627)520406907  |0 (DE-576)299053156  |4 aut 
245 1 0 |a Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer  |c Thomas Hofner, Stephan Macher-Goeppinger, Corinna Klein, Teresa Rigo-Watermeier, Christian Eisen, Sascha Pahernik, Markus Hohenfellner, Andreas Trumpp, and Martin R. Sprick 
264 1 |c 1 Dec 2013 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 13.07.2021 
520 |a Purpose: - - For rare cancers such as neuroendocrine bladder cancer treatment options are limited due partly to the lack of preclinical models. Techniques to amplify rare primary neuroendocrine bladder cancer cells could provide novel tools for the discovery of drug and diagnostic targets. We developed preclinical experimental models for neuroendocrine bladder cancer. - - Materials and Methods: - - Fresh tumor tissue from 2 patients with neuroendocrine bladder cancer was used to establish in vitro and in vivo models. We analyzed additional archived tissues in the National Center of Tumor Diseases tissue bank from patients with neuroendocrine bladder cancer. Primary tumor samples were collected during radical cystectomy. PHA-665752 was used to inhibit MET in animal models and cell cultures. The expression of markers and drug targets in neuroendocrine bladder cancer was determined by flow cytometry. The growth of neuroendocrine bladder cancer in vitro was determined by counting live cells. Tumor growth in mice was assessed by measuring tumor volume. Groups were compared using the nonparametric Kruskal-Wallis test. - - Results: - - Xenograft models and serum-free cultures of neuroendocrine bladder cancer cells allowed screening for cell surface markers and drug targets. We found expression of the HGF receptor MET in neuroendocrine bladder cancer cultures, xenograft models and primary patient sections. The growth of neuroendocrine bladder cancer spheroids in vitro depended critically on HGF. Treatment of neuroendocrine bladder cancer bearing mice with a MET inhibitor significantly decreased tumor growth compared to that in control treated mice. - - Conclusions: - - Neuroendocrine bladder cancer xenografts and serum-free cultures provided suitable models in which to identify diagnostic markers and therapeutic targets. Using the models, we noted HGF dependent growth of human neuroendocrine bladder cancer and identified MET as a new treatment target for neuroendocrine bladder cancer. 
650 4 |a animal 
650 4 |a carcinoma 
650 4 |a disease models 
650 4 |a HGF protein 
650 4 |a human 
650 4 |a neuroendocrine 
650 4 |a proto-oncogene proteins c-met 
650 4 |a urinary bladder 
700 1 |a Macher-Göppinger, Stephan  |e VerfasserIn  |0 (DE-588)1022394061  |0 (DE-627)716963299  |0 (DE-576)365275034  |4 aut 
700 1 |a Klein, Corinna  |e VerfasserIn  |0 (DE-588)1096836874  |0 (DE-627)856972762  |0 (DE-576)468109633  |4 aut 
700 1 |a Rigo Watermeier, Teresa  |e VerfasserIn  |0 (DE-588)1076143393  |0 (DE-627)834475839  |0 (DE-576)444996494  |4 aut 
700 1 |a Eisen, Christian  |e VerfasserIn  |0 (DE-588)1044693274  |0 (DE-627)77253635X  |0 (DE-576)398068283  |4 aut 
700 1 |a Pahernik, Sascha  |d 1968-  |e VerfasserIn  |0 (DE-588)122063163  |0 (DE-627)081713495  |0 (DE-576)293073147  |4 aut 
700 1 |a Hohenfellner, Markus  |d 1958-  |e VerfasserIn  |0 (DE-588)133862518  |0 (DE-627)557857988  |0 (DE-576)300155263  |4 aut 
700 1 |a Trumpp, Andreas  |d 1964-  |e VerfasserIn  |0 (DE-588)1081774134  |0 (DE-627)846650266  |0 (DE-576)454773552  |4 aut 
700 1 |a Sprick, Martin  |e VerfasserIn  |0 (DE-588)1183116942  |0 (DE-627)1663038716  |4 aut 
773 0 8 |i Enthalten in  |t The journal of urology  |d New York, NY [u.a.] : Elsevier, 1917  |g 190(2013), 6, Seite 2263-2270  |h Online-Ressource  |w (DE-627)313118213  |w (DE-600)2007912-6  |w (DE-576)095660194  |x 1527-3792  |7 nnas  |a Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer 
773 1 8 |g volume:190  |g year:2013  |g number:6  |g pages:2263-2270  |g extent:8  |a Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer 
856 4 0 |u https://doi.org/10.1016/j.juro.2013.06.053  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.auajournals.org/doi/10.1016/j.juro.2013.06.053  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210713 
993 |a Article 
994 |a 2013 
998 |g 1183116942  |a Sprick, Martin  |m 1183116942:Sprick, Martin  |d 140000  |e 140000PS1183116942  |k 0/140000/  |p 9  |y j 
998 |g 1081774134  |a Trumpp, Andreas  |m 1081774134:Trumpp, Andreas  |d 140000  |e 140000PT1081774134  |k 0/140000/  |p 8 
998 |g 133862518  |a Hohenfellner, Markus  |m 133862518:Hohenfellner, Markus  |d 910000  |d 910200  |e 910000PH133862518  |e 910200PH133862518  |k 0/910000/  |k 1/910000/910200/  |p 7 
998 |g 122063163  |a Pahernik, Sascha  |m 122063163:Pahernik, Sascha  |d 50000  |d 910000  |d 910200  |e 50000PP122063163  |e 910000PP122063163  |e 910200PP122063163  |k 0/50000/  |k 0/910000/  |k 1/910000/910200/  |p 6 
998 |g 1076143393  |a Rigo Watermeier, Teresa  |m 1076143393:Rigo Watermeier, Teresa  |d 140000  |e 140000PR1076143393  |k 0/140000/  |p 4 
998 |g 1022394061  |a Macher-Göppinger, Stephan  |m 1022394061:Macher-Göppinger, Stephan  |d 910000  |d 912000  |e 910000PM1022394061  |e 912000PM1022394061  |k 0/910000/  |k 1/910000/912000/  |p 2 
998 |g 132286963  |a Höfner, Thomas  |m 132286963:Höfner, Thomas  |d 910000  |d 910200  |e 910000PH132286963  |e 910200PH132286963  |k 0/910000/  |k 1/910000/910200/  |p 1  |x j 
999 |a KXP-PPN1762793458  |e 3949573569 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"pubHistory":["1.1917 -"],"origin":[{"publisherPlace":"New York, NY [u.a.] ; Hagerstown, Md.","dateIssuedKey":"1917","dateIssuedDisp":"1917-","publisher":"Elsevier ; Lippincott Williams & Wilkins"}],"note":["Gesehen am 25.03.2022"],"recId":"313118213","language":["eng"],"id":{"eki":["313118213"],"zdb":["2007912-6"],"issn":["1527-3792"]},"corporate":[{"role":"isb","display":"American Urological Association"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancerThe journal of urology","part":{"text":"190(2013), 6, Seite 2263-2270","year":"2013","pages":"2263-2270","issue":"6","volume":"190","extent":"8"},"title":[{"title_sort":"journal of urology","subtitle":"official journal of the American Urological Society","title":"The journal of urology"}]}],"recId":"1762793458","note":["Gesehen am 13.07.2021"],"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"1 Dec 2013"}],"id":{"eki":["1762793458"],"doi":["10.1016/j.juro.2013.06.053"]},"physDesc":[{"extent":"8 S."}],"title":[{"title":"Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer","title_sort":"Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer"}],"person":[{"display":"Höfner, Thomas","given":"Thomas","role":"aut","family":"Höfner"},{"family":"Macher-Göppinger","given":"Stephan","display":"Macher-Göppinger, Stephan","role":"aut"},{"family":"Klein","given":"Corinna","display":"Klein, Corinna","role":"aut"},{"family":"Rigo Watermeier","role":"aut","given":"Teresa","display":"Rigo Watermeier, Teresa"},{"role":"aut","display":"Eisen, Christian","given":"Christian","family":"Eisen"},{"given":"Sascha","display":"Pahernik, Sascha","role":"aut","family":"Pahernik"},{"family":"Hohenfellner","role":"aut","display":"Hohenfellner, Markus","given":"Markus"},{"given":"Andreas","display":"Trumpp, Andreas","role":"aut","family":"Trumpp"},{"family":"Sprick","role":"aut","display":"Sprick, Martin","given":"Martin"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Thomas Hofner, Stephan Macher-Goeppinger, Corinna Klein, Teresa Rigo-Watermeier, Christian Eisen, Sascha Pahernik, Markus Hohenfellner, Andreas Trumpp, and Martin R. Sprick"]},"language":["eng"]} 
SRT |a HOEFNERTHODEVELOPMEN1201